Editor’s Note: After more than a decade of strategic efforts led by CHEST, the Centers for Medicare & Medicaid Services (CMS) recently finalized a new national coverage document that includes substantial changes to federal coverage guidelines for noninvasive ventilation devices used in the home. These guidelines reflect nearly all of the major recommendations submitted by a CHEST-convened expert panel.
Any pulmonologist or sleep medicine clinician who has cared for a patient with COPD in need of BPAP knows the ordeal of securing appropriate therapy. For decades, clinicians have had to navigate algorithms that often felt like unsolvable puzzles—with patients’ lives at stake. In June 2025, the US Centers for Medicare & Medicaid Services (CMS) released long-awaited updates to its national coverage determination (NCD) for noninvasive positive pressure ventilation (NIPPV) in cases of chronic respiratory failure due to COPD.1 These revisions reflect years of sustained advocacy by pulmonary and sleep clinicians, patient advocates, and professional associations such as CHEST.
While the policy shift is welcome, it is important to acknowledge that it is grounded in a strong physiologic and clinical rationale. In COPD, chronic hypercapnia develops primarily from alveolar hypoventilation driven by increased dead space ventilation, ventilation-perfusion (V/Q) mismatch, elevated airway resistance, increased work of breathing, and dynamic hyperinflation. The physiologic rationale for NIPPV in this setting centers on reducing persistently elevated carbon dioxide levels, which are linked to increased susceptibility to infection, immune dysregulation, and airway dysfunction. Additional benefits include unloading of the respiratory muscles, improved sleep quality, and reduced cardiovascular strain.
Evidence supporting the use of NIPPV in COPD comes from two landmark randomized clinical trials. In 2014, Köhnlein and colleagues showed that NIPPV reduced one-year mortality among patients with clinically stable COPD when a reduction in PaCO2 was targeted.2 Three years later, Murphy and colleagues demonstrated that, in patients with persistent hypercapnia following an acute exacerbation, home NIPPV significantly prolonged the time to hospital readmission or death at 12 months.3 In both trials, patients received “high-intensity ventilation,” with driving pressures typically between 15 and 20 cm H2O and backup respiratory rates of 14 to 16 breaths per minute. These findings directly informed subsequent European Respiratory Society and American Thoracic Society guidelines, published in 2019 and 2020, respectively.4–5
Prior CMS guidelines
Despite this evidence base, implementation within the United States remained constrained by outdated CMS coverage criteria. The prior Medicare guidance for respiratory assist devices (RADs) did not align with COPD pathophysiology. Clinicians were required to demonstrate sleep oximetry with oxygen saturations ≤88% while patients were already receiving supplemental oxygen—a hurdle both irrelevant and often unattainable. Even when met, coverage permitted only BPAP without a backup rate, falling short of the high-intensity strategies validated in clinical trials. These barriers pushed many clinicians to circumvent RAD prescriptions entirely, instead turning to more costly home mechanical ventilators (HMVs) to deliver appropriate therapy. While patients often did gain access to effective treatment through the HMV pathway, this approach came at a significant financial burden to the health care system.
Guideline updates
The updated CMS guidance marks a significant shift in how RADs can be prescribed for patients with COPD. Most notably, the nonphysiologic requirement for sleep oximetry has been eliminated, dramatically improving access. Under the new criteria, a RAD may be prescribed for any patient with stable COPD who meets two conditions: an arterial blood gas (ABG) showing PaCO2 ≥ 52 mmHg while awake on prescribed oxygen, and the absence of sleep apnea as the predominant cause of hypercapnia (no formal testing required).
CMS has also introduced coverage for RAD initiation immediately following hospital discharge when clinicians judge a patient to be at risk of acute decompensation in the absence of therapy. This provision closes a dangerous care gap by allowing patients to transition directly to home therapy without delay.
Once prescribed, RAD use must be reassessed at least twice in the first year. Patients are expected to demonstrate adherence—defined as at least four hours of nightly use on 70% of days—and efficacy, either through stabilization of PaCO2 levels or through relief of symptoms such as headache, fatigue, dyspnea, confusion, or poor sleep quality.
Importantly, the updated guidance still preserves access to HMVs when clinically appropriate. These devices remain an option for patients requiring higher levels of support, such as those needing ≥4 L/min of supplemental oxygen, more than eight hours of daily ventilatory assistance, additional safety features like alarms and backup batteries, or in cases where the treating clinician determines that RAD therapy alone is unlikely to achieve physiologic or symptomatic goals.
Future directions
While the updated CMS guidelines represent an important victory for patients, clinicians, and the health care system, several caveats remain. Current coverage decisions are largely informed by randomized trials of high-intensity NIPPV in patients with advanced COPD with severe airflow limitation (mean FEV1 <30% predicted). The ventilatory strategies applied in these studies—high inspiratory and low expiratory pressures with a set backup rate—were employed to match the physiology of individuals with high dead space ventilation and substantial ventilatory load. In real-world practice, however, patients with less severe COPD may have multiple contributors to hypercapnia, including OSA, obesity, or medication effects, which may require alternative approaches to ventilation.
Moreover, the elimination of pulmonary function test (PFT) requirements, while reducing barriers to coverage, does not obviate the role of PFTs in diagnosis and management. COPD, by definition, requires spirometric confirmation, and PFTs remain essential for understanding disease severity and tailoring therapy.
Looking ahead, gaps remain in Medicare coverage for other causes of chronic respiratory failure. Patients with nonprogressive neuromuscular disease (eg, diaphragmatic paralysis), obesity hypoventilation syndrome, and multifactorial respiratory failure (such as restrictive thoracic disease or heart failure) continue to face inadequate access under current policy. Emerging evidence suggests that patients with chronic hypercapnic respiratory failure—regardless of etiology—may derive benefit from NIPPV.6 To fully realize this potential, future updates must move beyond disease-specific criteria and focus on the underlying pathophysiology of hypoventilation.
Achieving this will require both policy evolution and clinical innovation. Expanded training of clinicians in chronic respiratory failure management, as well as the design of pragmatic clinical trials across diverse patient populations, will be critical.7 Ultimately, the updated CMS determination represents a model for how advocacy, physiology, and evidence can align to improve patient care.
This article was originally published in the Winter 2025 issue of CHEST Physician.
References
1. Centers for Medicare & Medicaid Services. Noninvasive Positive Pressure Ventilation (NIPPV) in the Home for the Treatment of Chronic Respiratory Failure consequent to COPD (Decision Memo). Published June 9, 2025.
2. Köhnlein T, Windisch W, Köhler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir Med. 2014;2(9):698-705. doi:10.1016/S2213-2600(14)70153-5
3. Murphy PB, Rehal S, Arbane G, et al. Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA. 2017;317(21):2177-2186. doi:10.1001/jama.2017.4451
4. Macrea M, Oczkowski S, Rochwerg B, et al. Long-term noninvasive ventilation in chronic stable hypercapnic chronic obstructive pulmonary disease. an official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;202(4):e74-e87. doi:10.1164/rccm.202006-2382ST
5. Ergan B, Oczkowski S, Rochwerg B, et al. European Respiratory Society guidelines on long-term home non-invasive ventilation for management of COPD. Eur Respir J. 2019;54(3). doi:10.1183/13993003.01003-2019
6. Jimenez JV, Ackrivo J, Hsu JY, et al. Lowering PCO₂ with noninvasive ventilation is associated with improved survival in chronic hypercapnic respiratory failure. Respir Care. 2023;68(12):1613-1622. doi:10.4187/respcare.10813
7. Cao M, Katz SL, Hansen-Flaschen J. Roadmap for advancing a new subspecialty in pulmonary medicine devoted to chronic respiratory failure. Ann Am Thorac Soc. 2024;21(5):692-695. doi:10.1513/AnnalsATS.202309-810IP
